Research graph
References from Molecular Profiling of Tisotumab Vedotin–Treated Patients Identifies Immune Pathways Associated with Clinical Activity. Local targets link to admitted publications; unresolved targets remain external evidence.
A review of the clinical efficacy of FDA-approved antibody–drug conjugates in human cancers
10.1186/s12943-024-01963-7 · 2024 · External reference
Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment
10.1038/s41568-025-00869-w · 2025 · External reference
Beyond thrombosis: the impact of tissue factor signaling in cancer
10.1186/s13045-020-00932-z · 2020 · External reference
Systematic study of tissue factor expression in solid tumors
10.1002/cnr2.1699 · 2023 · External reference
The relationship between tissue factor and cancer progression: insights from bench and bedside
10.1182/blood-2011-06-317685 · 2012 · External reference
An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors
10.1158/0008-5472.can-13-2440 · 2014 · External reference
High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates
10.1158/1535-7163.mct-14-0798 · 2015 · External reference
Abstract 221: tisotumab vedotin induces anti-tumor activity through MMAE-mediated, Fc-mediated, and Fab-mediated effector functions in vitro
10.1158/1538-7445.am2019-221 · 2019 · External reference
An antibody-drug conjugate directed to tissue factor shows preclinical antitumor activity in head and neck cancer as a single agent and in combination with chemoradiotherapy
10.1158/1535-7163.mct-23-0298 · 2024 · External reference
617 Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death
10.1136/jitc-2020-sitc2020.0617 · 2020 · External reference
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
10.1016/s1470-2045(21)00056-5 · 2021 · External reference
Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer
10.1158/1078-0432.ccr-19-2962 · 2020 · External reference
Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries
10.1006/jmbi.1993.1203 · 1993 · External reference
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
10.1016/j.ebiom.2019.102625 · 2020 · External reference
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity
10.1021/bc0502917 · 2006 · External reference
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
10.1038/nbt832 · 2003 · External reference
The Molecular Signatures Database (MSigDB) hallmark gene set collection
10.1016/j.cels.2015.12.004 · 2015 · External reference
Exploring the role of target expression in treatment efficacy of antibody-drug conjugates (ADCs) in solid cancers: a comprehensive review
10.1007/s11912-024-01576-9 · 2024 · External reference
53 Assessing the mechanism of action (MOA) of tisotumab vedotin (TV) in head and neck squamous cell carcinoma (HNSCC) with digital pathology analysis of H&E images from innovaTV207 part C
10.1136/jitc-2025-sitc2025.0053 · 2025 · External reference
